NCT07594899 AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL Status NOT_YET_RECRUITING Phase PHASE2
NCT07585747 A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide Status NOT_YET_RECRUITING Phase PHASE2
NCT07562022 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma Status NOT_YET_RECRUITING Phase PHASE3
NCT07560449 QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms Status NOT_YET_RECRUITING Phase PHASE2
NCT07485647 Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing Status NOT_YET_RECRUITING Phase PHASE2
NCT07465029 A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain Status ACTIVE_NOT_RECRUITING Phase N/A
NCT07460362 Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma Status RECRUITING Phase PHASE2
NCT07448324 Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL Status RECRUITING Phase PHASE2
NCT07428369 A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Status NOT_YET_RECRUITING Phase PHASE2/PHASE3
NCT07384624 Combining Latency Reversing Agents to Address the HIV Reservoir Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07341867 Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Status NOT_YET_RECRUITING Phase PHASE1
NCT07297329 A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant Status RECRUITING Phase PHASE3
NCT07285239 Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Status NOT_YET_RECRUITING Phase PHASE3
NCT07261163 Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma Status RECRUITING Phase PHASE2
NCT07247097 ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma Status NOT_YET_RECRUITING Phase PHASE2
NCT07240194 The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study Status RECRUITING Phase PHASE2
NCT07208981 Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL Status RECRUITING Phase PHASE2
NCT07189065 A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma Status RECRUITING Phase PHASE2
NCT07187167 Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease Status RECRUITING Phase PHASE2
NCT07184424 Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC Status COMPLETED Phase NA